Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.

@article{Naylor2011ProteinKC,
  title={Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.},
  author={Tara L. Naylor and Huaping Tang and Boris A Ratsch and Andreas Enns and Alice Loo and Liqing Chen and Peter Lenz and Nigel J. Waters and Walter Schuler and Bernd Doerken and Yung-mae Yao and Markus Warmuth and Georg Lenz and Frank Stegmeier},
  journal={Cancer research},
  year={2011},
  volume={71 7},
  pages={2643-53}
}
The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) correlates with poor prognosis. The ABC subtype of DLBCL is associated with constitutive activation of the NF-κB pathway, and oncogenic lesions have been identified in its regulators, including CARD11/CARMA1 (caspase recruitment domain-containing protein 11), A20/TNFAIP3, and CD79A/B. In this study, we offer evidence of therapeutic potential for the selective PKC (protein kinase C) inhibitor sotrastaurin (STN) in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
42 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

inventors. Preparation of aminopyrimidines as IKK inhibitors for treating autoimmune diseases and inflammations

  • B Bollbuck, A Denholm, J Eder, R Hersperger, P Janser, L Revesz
  • 2004
Highly Influential
2 Excerpts

Similar Papers

Loading similar papers…